International Lung Cancer Congress Research Articles

Cooperative Group Research Efforts in Thoracic Malignancies 2009: A Review From the 10th Annual International Lung Cancer Congress

Cooperative Group Research Efforts in Thoracic Malignancies 2009: A Review From the 10th Annual International Lung Cancer Congress

Demographic and Clinical Factors Related to Carboplatin Toxicity

01 Clinical Lung Cancer, Vol. 10, No. 5, E5, 2009; DOI: 10.3816/CLC.2009.n.054 Demographic and Clinical Factors Related to Carboplatin Toxicity Sanjay J. Ayirookuzhi, Jerry McLarty, Richard P. Mansour, Glenn M. Mills LSU Health Sciences Center, Division of Hematology-Oncology/Feist-Weiller Cancer Center, Shreveport, LA Background: Carboplatin is a commonly used drug in stage III/IV non–small-cell lung cancer (NSCLC). Myelosuppression is a common toxicity of carboplatin, and this study aimed to assess the relationship between different demographic and descriptive factors and myelosuppression. Patients and Methods: Data from patients with stage III and IV NSCLC seen between January 1, 1999, and December 31, 2007, were analyzed. Patients who received concurrent radiation, had died before the first cycle was completed, or who had missing laboratory values were excluded. Only the first cycle of the carboplatin-based regimen was used for analysis with nadir platelets, hemoglobin, and white blood cell counts (WBCs) used as endpoints. SPSS software was used for statistical analysis including Pearson correlation, analysis of covariance (ANCOVA), independent t tests, and multivariate linear regression models. Results: Of the 216 patients initially abstracted for analysis, only 132 patients qualified for analysis. Demographically, 71 were Caucasian, and the rest were African-American, while 92 were male. The t test to indicate whether nadirs were different by stage were significant for platelets (P = .015) and WBC (P < .0001) but not hemoglobin. t test for race was significant for nadir platelets (P = .008) and hemoglobin (P = .004) but not for nadir WBC. ANCOVA for nadir platelets was significantly related to baseline platelet levels (P < .0001), stage (P = .012) and approached significance for stage with sex (P = .054). ANCOVA performed for nadir hemoglobin was significantly related to race (P = .015), while ANCOVA for nadir WBC was statistically significantly related to BSA (P = .026), baseline WBC count (P < .000), race (P = .017), and stage at diagnosis (P = .045). Carboplatin dose was not found to be statistically significantly related to nadir platelet, WBC, or hemoglobin in these models. Conclusion: Carboplatin is a myelosuppressive drug, and a number of factors are related to its toxicity. Meeting Abstracts Abstracts From: The 10th International Lung Cancer Congress June 17-20, 2009; Kohala Coast, HIs From: The 10th International Lung Cancer Congress June 17-20, 2009; Kohala Coast, HI Program Directors: David R. Gandara, MD; Roy S. Herbst, MD, PhD Clinical Lung Cancer September 2009 | E5 Available Online at www.cigjournals.com

Abstracts From: The 10th International Lung Cancer Congress June 17–20, 2009; Kohala Coast, HI

Abstracts From: The 10th International Lung Cancer Congress June 17–20, 2009; Kohala Coast, HI

Influence of Initial Stage at Diagnosis on Length of Time to Develop Brain Metastasis as Initial Disease Recurrence in Non–Small-Cell Lung Cancer

Background: Brain metastasis is a major cause of mortality and morbidity in non–small-cell lung cancer (NSCLC). Timing of brain metastasis as initial disease recurrence (BMIDR) based on initial stage at diagnosis in NSCLC was of interest for potential follow-up brain imaging schedule development. Patients and Methods: A retrospective analysis on 4065 NSCLC cases with full staging information, seen between 1994 and 2006, at the Moffitt Cancer Center and Research Institute, Tampa, FL, was performed utilizing the cancer center’s registry data. A total of 283 (6.96%) patients developed BMIDR. Among them, 45 (1.1%) were patients who previously had brain metastasis at diagnosis and were treated. Results: At initial presentation, there were 488 with stage IA disease, 317 stage IB, 39 stage IIA, 185 stage IIB, 492 stage IIIA, 882 stage IIIB, and 1662 stage IV. A total of 477 of the patients with stage IV disease had brain metastasis at the time of diagnosis. A majority of patients who developed BMIDR had stage III or IV disease at the time of diagnosis. Stage was found to influence status as having BMIDR (P = .0003). A higher proportion of patients with stage IIIA disease had BMIDR than that of stage IIIB and IV, and patients with advanced NSCLC were mostly not surviving long enough to present with a recurrence. Median length of time to develop BMIDR is shown in Table 1. Conclusion: In NSCLC, length of time for BMIDR was generally shorter by a more advanced stage at diagnosis. Median time to develop BMIDR in patients with NSCLC with stage IIA to IV disease were within the first year from initial diagnosis. This information should be helpful for establishing follow-up brain imaging schedules in NSCLC based on the staging information at diagnosis. Online Abstracts From the 10th International Lung Cancer Congress

2005 Highlights From: 41st Annual Meeting of ASCO Orlando, FL, May 2005 6th International Lung Cancer Congress Kauai, Hawaii, June 2005 11th World Conference on Lung Cancer Barcelona, Spain, July 2005

2005 Highlights From: 41st Annual Meeting of ASCO Orlando, FL, May 2005 6th International Lung Cancer Congress Kauai, Hawaii, June 2005 11th World Conference on Lung Cancer Barcelona, Spain, July 2005